A deluge of DNA sequence and gene expression data generated in the last five years encouraged the original high-throughput mentality within genomics companies. Mapping the human genome provided the impetus for developing technologies for high-throughput DNA sequencing and analysis. Now genotyping, or the detection and analysis of individual genetic variations, has become the newest market around which companies are preaching the need for high-throughput methodologies.While only a handful of companies were directly involved in assisting the Human Genome Project, genotyping--the detection and analysis of individual genetic variations--has been fueling technology development, with applications in basic research through drug development. But in genotyping, high throughput is the goal but is not yet the reality. On the other hand, even if it's early to be talking about the successful integration of genotyping technologies and data, current players are already pushing their technologies onto their customers' platforms. If a company isn't already a player, it may be too late.
by Mark L. Ratner
A deluge of DNA sequence and gene expression data generated in the last five years encouraged the original high-throughput mentality...
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
MBX Biosciences reported Phase II results for once-weekly canvuparatide that showed comparable efficacy to Ascendis Pharma’s once-daily Yorvipath for hypoparathyroidism.
The biotech announced positive topline results from its pivotal study in Alexander disease, which has an estimated population of about 300 in the US.
Stealth won FDA accelerated approval for Forzinity, the first Barth syndrome therapy, after multiple regulatory setbacks. The decision sets the stage for confirmatory trials and expanded patient access.
The Belgium-based group has collected heaps of long-term efficacy and safety data which will help stave off the competition.
The Belgium-based group has collected heaps of long-term efficacy and safety data which will help stave off the competition.
The Phase III trial of the SERD has shown a significant benefit in the intent-to-treat and ESR1-mutated populations in post-CDK ER+/HER2- metastatic breast cancer but whether the data will be enough to support an equally broad approval remains to be seen.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
